- Benefits of regular comprehensive eye exams reinforced in analysis of military exams
- Doctors of optometry have safely performed thousands of optometric laser procedures
- Fun and vision-friendly holiday gift guides for kids
- Help patients understand the hazards of vaping to the eyes
- H5N1 ‘bird flu’ cases report conjunctivitis, teary eyes symptoms
- Link between eye examinations and fall prevention in older adults
- As eclipse edges closer, AOA promotes safe viewing
- Study underestimates doctors of optometry providing eye care to children
- Foresightedness on nearsightedness
- ‘Inadequate to meet demand’: Report spotlights declining ophthalmology workforce as America’s eye health needs grow
- AOA president: Annual eye exams set students up for success
- How doctors of optometry can help ease the burden for parents
- Doctors of optometry embrace myopia management
- The causes behind the causes
- human trafficking
- Wash, rinse, repeat: Reminding contact lens wearers about risky hygiene
- Keeping childrens vision in focus
- monkeypox national public health emergency
- July 4 can spark eye safety conversation with public
- FDA proposes eliminating cigarette cigar flavors
- Meeting the needs of an aging america
- multisystem diabetes prevention and management
- NEI releases detailed strategic plan on its priorities for the next five years
- A scary disconnect
- New partnership with MyEyeDr
- 10 reasons why you should be an InfantSEE provider
- Children’s vision-ultimate goal
- COVID-19 viral activity returning
- Doctors of optometry leaders in fight against myopia’s threat
- Stress test
- Eye and the storms
- AOA Emergency Children’s Vision Summit continues
- Childrens Vision Summit recap
- Pennsylvania doctors of optometry put high priority on children’s eye health and vision care
- AOA Children’s Vision Summit
- CDC updates COVID-19 eye protection
- Air pollution implicated in AMD study as US air quality declines
- Feds accelerate COVID-19 vaccination pace
- federally qualified health centers address underserved community eye care
- Doctors of optometry and staff preparing for next move in vaccine distribution
- AOA and affiliates advocate for optometry in Phase 1 COVID-19 vaccine distribution
- Twindemic Flu & COVID-19
- innovationing gene-editing technology
- Case study on overprescribing
- APHA urges preservation of children access to comprehensive vision care
- Do you know what your patients are searching for
- TBI and doctors of optometry
- doctors rebound from COVID-19 limitations settle into new normal
- contaminated hand sanitizer may cause methanol poisoning
- cigarette labels graphically depict smoking cataracts link
- Coronavirus emergency declared
- Excessive device use alters prekindergartners white brain matter
- FDA Drug Shortage Report
- FDA clears contact lens to slow myopia progression
- flu season on the way CDC urges early vaccines
- Vaping draws federal warnings rebuke amid billowing health concerns
- Doctors of optometry talk about ecigarette use
- Graphic warnings weighed to emphasize smokings health effects including blindness
- The cannabis conundrum
- Optometrys North Star
- Futuristic contact lens gains FDA marketing approval
- Amblyopias influence on sense of self
- Diabetes in young patients
- Diet soda habit associated with blinding diabetes complications
- The outlook for contact lenses
- OTC cold flu care What patients dont know can hurt them
- When Patients Lie to Doctors
- Comprehensive diabetes care
- Provide patients relief in winter spring summer and fall
- Meditation an adjunctive therapy for glaucoma
- doctors of optometry teammates in the post-concussion care
- When measles rush in
- Pressures on Understanding hypertensive guidelines
- The lowdown on vision rehabilitation
- Clean hands save sight
- 5 ways to offer neuro-optometric services in your practice
- Are you asking your patients about their e-cigarette use
- Ocular Manifestation of Lyme Disease
- March Madness
- Eye exams for Alzheimers
- Optometry seeking expanded role in diabetes care
- high calcium increase risk of AMD
- How to get hands-on with dry eye
- measles outbreak eye-catching for doctors of optometry
- prescribing fitting bioptic telescope system for driving
- Optometry is essential in care for patients with concussions TBIs
- prescribing and fitting a bioptic telescope system for driving part II
- Tips on providing optometric care for children with autism
- Screen time for children under 5
- Vision and batting
- Reading for the AMD patient
- Vision impairment cognitive decline go hand in hand
- doctors of optometry can provide a jump on inflammatory bowel disease treatment
- Legal doesn’t always mean safe in drivers vision
- Study pulls back covers on links between glaucoma and sleep
- Exploring the promise of retinal prostheses
- New resource helps doctors guide patients to proper sunglasses
- How fish insects could aid presbyopic patients
- Imaging over in person exams Telehealth study misses point
- InfantSEE helps young doctors of optometry build awareness and their practices
- community-health-centers
- VA VISION
- PedPosted
- Child-Health-Day
- Counterfeit Contact Lens Infections Study
- Dont delay vaccinate now
- Lather rinse repeat The DIY vaccine
- optometric surgical procedures courses
Study: Could atropine delay or prevent myopia in children?
March 2, 2023
Change in standard of care is not yet warranted, say doctors of optometry who wrote editorial for study. Additional research is needed.
Tag(s): Clinical Eye Care, Public Health
Nightly doses of atropine in young children may have the potential to delay or prevent the onset of myopia in children, say the authors of a new study.
The study was published Feb. 14 in JAMA online. The objective of the study was “to evaluate the efficacy of low-concentration atropine sulfate eyedrops at 0.05% and 0.01% concentration for delaying the onset of myopia” in children. The randomized trial was placebo-controlled, double-masked and included 474 nonmyopic children ages 4 through 9 with cycloplegic spherical equivalent between +1.00 D to 0.00 D and astigmatism of less than −1.00 D. The first treatment was administered in July 2017, with the final follow-up session in 2022. Over a two-year period, eyedrops were applied once nightly to both eyes of participants in each group (0.05%, 0.01% and placebo).
Per the findings:
- The two-year, cumulative incidence of myopia in the 0.05% atropine, 0.01% atropine, and placebo groups were 28.4%, 45.9% and 53%, respectively, and the percentages of participants with fast myopic shift at two years were 25.0%, 45.1%, and 53.9%.
- Compared with the placebo group, the 0.05% atropine group had significantly lower cumulative myopia incidence.
- Compared with the 0.01% atropine group, the 0.05% atropine group had significantly lower cumulative myopia incidence.
- The 0.01% atropine and placebo groups were not significantly different in cumulative myopia incidence or percentage.
“Among children aged 4 to 9 years without myopia, nightly use of 0.05% atropine eyedrops compared to those given the placebo doses showed a significantly lower incidence of myopia and lower percentage of participants with fast myopic shift at 2 years,” conclude the study’s authors who primarily were affiliated with The Chinese University of Hong Kong. “There was no significant difference between 0.01% atropine and placebo. Further research is needed to replicate the findings, to understand whether this represents a delay or prevention of myopia, and to assess longer-term safety.”
They add: “Prevention or delay of myopia onset may have the potential to improve long-term visual outcomes.”
Myopia: A public health threat
The incidence of myopia (nearsightedness) is growing at an alarming rate—with the study’s authors calling it a “worldwide public health threat.” Myopia, which is irreversible once it begins about age 8, is expected to affect 50% of the world’s population by 2050.
“Prescribing a treatment to those children most at risk before the onset of myopia may have a greater effect than slowing myopia progression after onset because it provides earlier intervention when eye growth and progression are fastest,” say David Berntsen, O.D., Ph.D., clinical sciences department chair, University of Houston College of Optometry, and Jeffrey Walline, O.D., Ph.D., associate dean for research at The Ohio State University. Drs. Berntsen and Walline co-authored an editorial, “Delaying the Onset of Nearsightedness,” that accompanies the JAMA article.
Toward that end, the LAMP2 study does increase understanding of the use of low concentrations of atropine to delay the onset of myopia, say Drs. Berntsen and Walline, who note in their editorial the risks associated with myopia—greater risk of sight-threatening complications and the nation’s financial burden due to treating myopia.
LAMP2 is the “first large-scale, 2-year randomized clinical trial to investigate the effects of nightly administration of 0.05% or 0.01% atropine eyedrops vs. placebo eyedrops in children without myopia,” the two doctors of optometry say in the editorial. It also builds on three previous studies that have focused on nightly administrations of atropine.
But there remain plenty of unknowns. For instance, can it delay myopia progression in adults or prevent myopia in children? What about a further look at side effects—the most common being photophobia reported by 15 study participants? Additional research will shed light, and that will take time.
“The LAMP2 study provides the strongest evidence to date that daily administration of 0.05% atropine delays the onset of myopia and meaningfully adds to the evidence that refractive error change and eye growth can be slowed, even before myopia onset,” they say. “However, the evidence presented does not yet warrant a change in the standard care of children because we do not yet know the long-term effects of delaying the onset of myopia with low-concentration atropine.
“Additionally, identifying whom to consider for treatment is a challenge because children who are not yet myopic do not routinely have their eyes examined by an eye care specialist unless they fail a routine vision screening test,” they add. “Ultimately, the implementation of vision screenings that include determining a child’s prescription will likely be needed to identify children most likely to become myopic who may benefit from low-concentration atropine. Additional randomized studies are needed to replicate these findings and to answer questions regarding the long-term outcomes.”
The study does hold promise.
“Delaying the onset of myopia is a novel way to potentially reduce the amount of myopia someone develops and possibly the risk of associated sight-threatening eye diseases in adulthood,” Drs. Berntsen and Walline say. “Delaying myopia onset also has the added benefit of additional time that young children do not have to wear vision correction. It is noteworthy that the nightly administration of low-concentration (0.05%) atropine eye drops over two years in the LAMP2 Study resulted in few side effects and a potentially meaningful benefit.
“This study provides doctors with evidence to support a new tool in the management of myopia by providing a way to potentially delay myopia onset for children most likely to become myopic,” they add. “However, pre-myopic children don’t typically receive eye examinations, so we need to change how we manage children at risk of myopia in order to identify and educate those who are most likely to benefit from this new treatment strategy. The LAMP2 Study, which enrolled children in China, found a benefit. Additional randomized studies also are needed to determine if the results are the same in other populations of children.”
Children’s vision resources
The AOA provides a number of resources that doctors of optometry can use in caring for children. Access these AOA members-only resources:
- View several children’s vision tools.
- Read Clinical Report: Myopia Management (2021) developed by the AOA Evidence-based Optometry Committee.